ReviewPatient education and counseling2014
Striking a balance in communicating pharmacogenetic test results: promoting comprehension and minimizing adverse psychological and behavioral response.
Review in Patient education and counseling, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 30 citations in OpenAlex.
- A feasibility study on implementing pre-emptive pharmacogenomics testing in outpatient clinics in Singapore (IMPT study).The pharmacogenomics journal · 2025Article
- Improving prescribing: a feasibility study of pharmacogenetic testing with clinical decision support in primary healthcare in Singapore.Family practice · 2024Article
- Article
- Assessment of the current status of real-world pharmacogenomic testing: informed consent, patient education, and related practices.Frontiers in pharmacology · 2024Article
- A randomized controlled trial of analogue pharmacogenomic testing feedback for psychotropic medications.PEC innovation · 2023Article
- Pharmacogenetic testing and counselling in the community pharmacy: mixed-methods study of a new pharmacist-led service.International journal of clinical pharmacy · 2023Article
- Pharmacogenomic knowledge and awareness among diverse patients treated with angiotensin converting enzyme inhibitors.Pharmacogenomics · 2023Article
- Personalizing Personalized Medicine: The Confluence of Pharmacogenomics, a Person's Medication Experience and Ethics.Pharmacy (Basel, Switzerland) · 2023Review
- Pharmacogenomics in practice: a review and implementation guide.Frontiers in pharmacology · 2023Review
- Preferences for and acceptability of receiving pharmacogenomic results by mail: A focus group study with a primarily African-American cohort.Journal of genetic counseling · 2021Article
- Knowledge and Attitudes About Genetic Testing Among Black and White Women with Breast Cancer.Journal of racial and ethnic health disparities · 2021Article
- Using a Genomics Taxonomy: Facilitating Patient Care Safety and Quality in the Era of Precision Oncology.Clinical journal of oncology nursing · 2021Article
- An assessment of patient perspectives on pharmacogenomics educational materials.Pharmacogenomics · 2020Article
- A stepwise approach to implementing pharmacogenetic testing in the primary care setting.Pharmacogenomics · 2019Article
- Parental Perception of Self-Empowerment in Pediatric Pharmacogenetic Testing: The Reactions of Parents to the Communication of Actual and Hypothetical CYP2D6 Test Results.Health communication · 2017Article
- Assessment of patient perceptions of genomic testing to inform pharmacogenomic implementation.Pharmacogenetics and genomics · 2017Article
- How can psychological science inform research about genetic counseling for clinical genomic sequencing?Journal of genetic counseling · 2015Article
- Ethical perspectives on translational pharmacogenetic research involving children.Paediatric drugs · 2015Review
- Assessing patient understanding of pharmacogenomic test results: a qualitative study.PharmacogenomicsArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
objectivePharmacogenetic (PGx) testing can provide information about a patient's likelihood to respond to a medication or experience an adverse event, and be used to inform medication selection and/or dosing. Promoting patient comprehension of PGx test results will be important to improving engagement and understanding of treatment decisions.
methodsThe discussion in this paper is based on our experiences and the literature on communication of genetic test results for disease risk and broad risk communication strategies.
resultsClinical laboratory reports often describe PGx test results using standard terminology such as 'poor metabolizer' or 'ultra-rapid metabolizer.' While this type of terminology may promote patient recall with its simple, yet descriptive nature, it may be difficult for some patients to comprehend and/or cause adverse psychological or behavioral responses.
conclusionThe language used to communicate results and their significance to patients will be important to consider in order to minimize confusion and potential psychological consequences such as increased anxiety that can adversely impact medication-taking behaviors. PRACTICE IMPLICATIONS: Due to patients' unfamiliarity with PGx testing and the potential for confusion, adverse psychological effects, and decreased medication adherence, health providers need to be cognizant of the language used in discussing PGx test results with patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.